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Effects of nifedipine and enalapril on glomerular structure and function
in uninephrectomized SHR. Spontaneously hypertensive rats (SHR) that
underwent uninephrectomy (UNX) at six weeks of age were randomly
assigned to receive no treatment, the calcium channel blocker, nife-
dipine, or the angiotensin converting enzyme inhibitor, enalapril. Both
drugs reduced systemic blood pressure, however, blood pressure
tended to be greater in rats given nifedipine than in those on enalapril.
After six months, proteinuria and the prevalence of glomerular sclerosis
were significantly reduced in the two treated groups compared to values
observed in untreated SHR. Kidney weight was also reduced by
therapy, suggesting that both enalapril and nifedipine inhibited compen
satory kidney growth. Micropuncture studies performed in similarly
treated groups of rats, but at 11 weeks of age, revealed that PGC was
elevated in untreated UNX SHR and reduced by both nifedipine and
enalapril. These findings support the hypothesis that glomerular hyper-
tension and renal hypertrophy are important risk factors for glomerular
injury. They suggest that calcium blockers are as effective as angioten-
sin converting enzyme inhibitors in preventing progressive kidney
damage.
The spontaneously hypertensive rat (SHR) is a model of
severe systemic hypertension and progressive kidney damage.
By one year of age, untreated SHR develops proteinuria and
glomerular sclerosis which is largely limited to juxtamedullary
nephrons [1]. The renal disease is more severe if SHR undergo
uninephrectomy (UNX) at an early age; pathologic proteinuria
is observed after only six months, and both superficial and deep
nephrons become sclerotic [2]. As is the case in rats with
remnant kidneys (RK) [3, 4] or desoxycorticosterone-salt hy-
pertension (DS) [5, 6], glomerular injury in UNX SHR has been
associated both with elevation in glomerular capillary pressure
(Gc) [2] and renal hypertrophy [71. Furthermore, maneuvers
which either reduce P [2, 3] or inhibit kidney growth [71
lessen damage.
The UNX SHR, RK and DS models are also similar in that
antihypertensive drugs can reduce glomerular injury [3, 6, 8, 91
in all three. Based primarily upon studies in RK [9] and DS rats
[101, it has been suggested that angiotensin converting enzyme
inhibitors (CE!) may be superior to other agents in their ability
to protect the kidney. However, both the RK and DS models
can be criticized as being unlike most patients at risk for
progressive kidney failure. In the DS model, hypertension
depends upon an excess of mineralocorticoid, an unusual
occurrence in human disease. The RK model involves an
extreme reduction in renal mass, an initial deficit in renal
function far in excess of that which apparently places patients at
risk for progressive filtration failure. In both models, severe
injury is present after one to two weeks and progresses rapidly
[3, 51. This is in contrast to human renal disease, which usually
advances slowly over many years. Finally, in both the DS and
RK model, antihypertensive therapy with diuretics and hydrala-
zine fails to prevent kidney damage [9, 111. Although limited
data is available concerning the relative efficacy of various
agents in humans, when administered in combination with a
beta adrenergic blocker, these drugs may decrease the rate at
which renal function is lost in patients with diabetic nephrop-
athy [12].
In many of these aspects, the UNX SHR differs significantly
from the DS and RK models. Hypertension in SHR does not
depend upon overt volume overload or mineralocorticoid ex-
cess. The 50% reduction in GFR imposed by UNX is similar in
magnitude to the degree of functional impairment initially
observed in many patients who are at risk for progressive
kidney failure, The pace of disease is slow, glomerular lesions
develop over six months, which represents 50% of the life
expectancy of the rat [21. Finally, we have demonstrated that
diuretics and hydralazine prevent kidney damage in this model
[10], a response similar to that described in diabetic patients
[121. These observations suggest that studies in the UNX SHR
model may provide novel insights into the pathophysiology of
progressive glomerular sclerosis.
Calcium channel blockers are potent vasodilators recently
approved for the treatment of hypertension. To date, conflicting
data has been published concerning the ability of this class of
drugs to prevent glomerular hypertension, hypertrophy and
injury [6, 13, 14]. Furthermore, the majority of studies have
been performed in a single model, the rat with a remnant
kidney. To further examine the effects of a CCB on glomerular
structure and function, we administered the dihydropyridine,
nifedipine to UNX SHR and compared its actions to the CE!,
enalapril.
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Methods
Description of groups
Studies were performed in six groups of SHR which under-
went right nephrectomy at six weeks of age. Three groups were
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followed for 36 weeks. Control (CON) rats (N = 7) were fed
standard rat chow (Purina, Richmond, Indiana, USA) and given
tap water to drink. NIF rats (N = 8) were fed identical chow to
which nifedipine (0.25% by weight) was added, and given tap
water to drink. This dose of nifedipine was selected based upon
preliminary studies (data not shown) in which it was determined
to be the lowest dose which resulted in long term control of
systemic hypertension in UNX SHR. ENP rats (N = 8)
received standard chow and tap water to which enalapril 150
mg/liter had been added. This was previously determined to be
an effective antihypertensive dose in this model [101. Rats were
not pair fed but had free access to food and water. Because
nifedipine is light sensitive, NIF rats were provided with fresh
chow each evening. Additional groups of CON, NIF and ENP
rats underwent micropuncture studies of glomerular hemody-
namics at eleven weeks of age, five weeks after nephrectomy.
At this stage, sustained hypertension has developed and the
hemodynamic response to nephrectomy is complete, however,
neither proteinuria nor morphologic evidence of damage is
present [2, 10].
Design of the long term study
Animals in the long-term study were placed in metabolic
cages for monthly determinations of 24-hour urinary protein
excretion. Awake systolic blood pressure was also measured at
four week intervals using a photoelectric tail cuff device (Model
29 IITC Inc., Woodland Hills, California, USA) attached to a
recorder (Model SE 120, IITC Inc.). For each rat, the value
recorded represented the mean of four to six measurements
obtained at a single sitting.
Thirty-six weeks after UNX, the rats were anesthetized with
mactin (100 mg/kg, i.p.). A polyethylene catheter (PESO) was
inserted into the femoral artery and arterial pressure was
measured by a Statham P23B pressure transducer connected to
a Grass recorder (Model 7A, Statham Instruments, Quincy,
Massachusetts, USA). A tracheostomy was then performed and
polyethylene catheters were inserted into both jugular veins and
the left ureter for infusion of test substances and collection of
urine. To compensate for surgical losses and specimens drawn,
all rats received an intravenous infusion of isoncotic rat plasma
of 10 ml/kg body weight at a rate of 0.1 mi/mm, followed by a
sustaining infusion of plasma at a rate of 0.5 mI/hr. The rats also
received a 0.5 ml intravenous bolus of inulin (10 g/lOO ml) in
saline followed by an infusion of 1.0 mi/hour. After a 45-minute
equilibration period, two timed urine collections of fifteen
minutes each were made. At the midpoint of each collection,
100 pi of blood was collected in microhematocrit tubes. At the
conclusion of the clearance study, the kidneys were fixed in situ
by perfusion for five minutes at the measured blood pressure
with 1.25% glutaraldehyde in 0.1 M cacodylate buffer. The
kidney was excised and weighed.
Morphologic studies
Two coronal slices of each kidney were processed routinely
for light microscopy through paraffin embedding. Sections 3 t
thick were stained with hematoxylin/eosin and periodic acid-
Schiff. The incidence of glomerular sclerosis was quantitatively
assessed in a blinded fashion by one observer (H.F.). On
average, 197 glomeruli were examined in each rat. The percent-
age of glomeruli with glomerular sclerosis was calculated for
each animal by dividing the number of abnormal glomeruli by
the total number examined.
Analytical techniques
Inulin concentrations were determined by the anthrone
method [15], and inulin clearance was calculated by the stan-
dard formula.
Urine protein concentration was measured by precipitation
with 3% sulfosalicylic acid and turbidity was determined by
measuring absorbance at 595 A with a spectrophotometer.
Micropuncture studies
Micropuncture studies were performed in rats at 11 weeks of
age. Rats were anesthetized with 100 mg/kg of mactin, and
prepared in the standard fashion for micropuncture [161. A
tracheostomy was performed and polyethylene catheters in-
serted into jugular veins, femoral artery and ureter for infusion
of solutions and collection of samples. The kidney was exposed
via a subcostal incision, placed on a lucite holder and illumi-
nated with a fiberoptic light. All rats received an initial infusion
of isoncotic plasma equal to 10 mllkg body weight followed by
a sustained infusion of plasma at approximately 0.5 mi]hr
adjusted to maintain a stable hematocrit. Rats also received a
0.5 ml i.v. bolus of 3H methoxyinulin followed by a sustaining
infusion at a rate of 0.5 mI/hr. Timed collections of proximal
tubule fluid were obtained by micropuncture for determination
of inulin concentration by liquid scintillation counting. Urine
and plasma content of inulin was measured by the same method
and SNGFR and GFR were calculated by the standard formulas
[16]. Efferent arteriolar blood samples were obtained for the
measurement of total protein concentration by the method of
Viets et al [17]. Hydraulic pressure in cortical tubules and
efferent arterioles was measured directly using the servo-null
micropipette technique [16]. Mean glomerular capillary hydrau-
lic pressure was estimated using the stop-flow pressure, as
described by Allison, Lipham and Gottschalk [18]. The deter-
minants of ultrafiltration and segmental vascular resistances
were calculated using the formulas as set out by Baylis et al
[16].
Statistics
Statistical analysis of glomerular sclerosis data was per-
formed by the Kruskall-Wallis test (chi square approximation),
and for all other data by one-way analysis of variance followed
by computation of modified t-values and multiple pairwise
comparisons according to the method of Bonferroni. Statistical




Although the rats were not pair fed, rats in all groups had free
access to food and water and gained a similar amount of weight
from time of nephrectomy to time of sacrifice. Because the
protein content of the diets were identical, this finding also
suggests that protein intake was similar among the groups. Final
weights averaged 389 10, 401 9 and 374 9 g in CON, NIF
and ENP, respectively. These values were not significantly
different.




Fig. 1. Awake systolic blood pressure in rats aged 14 to 38 weeks.
Blood pressure in CON was significantly greater than that observed in
NIF and ENP at all times. Pressure in NIF significantly exceeded that
in ENP at 14, 18, 34 and 38 weeks of age. Data are means SE; Groups
are defined in the text. Symbols are: (0) CON; (•) NIF; (V) ENP.
As summarized in Figure 1, severe systolic hypertension was
already present in untreated SHR by the time of the initial
systolic pressure determination at 12 weeks of age. Systolic
pressure was always in excess of 200 mm Hg in this group.
Administration of both nifedipine and enalapril was associated
with a reduction in pressure, however, systolic pressure tended
to be greater in NIF as compared to ENP rats.
Figure 2 displays protein excretion data for these three
groups of rats. Proteinuria increased with age in all groups,
however, the magnitude of this increase was significantly re-










CON 7 181 4 2.44 0.21 2,94 0.08 0.76 0.03
NIF 8 126 4 1.86 0.18 2.63 0.08k' 0.66 o.o2
ENP 7 115 4 2.15 0.15 2.56 0,09a 0.68 0.03k'
excreted 69.6 9.5 mg/24 hr of protein, a value significantly
...j greater than that observed in NIF (36.7 5.0) and ENP (20.2
40 1.3). The mean values observed in the two treated groups were
not statistically different at any point during the study.
The morphologic changes which develop in glomeruli of
UNX SHR have been described previously in detail [2, 101. On
average, 24.0 2.6% of glomeruli were either globally or
focally sclerotic in untreated rats. The prevalence of these
lesions was significantly (P < 0.005) reduced to 8.0 2.8% in
NIF and 5.3 0.8% in ENP treated rats, respectively. The
mean values observed in the two treated groups were not
* statistically different.
The effects of 36 weeks of therapy on mean arterial pressure
(MAP) measured at the time of sacrifice, glomerular filtration
rate (GFR) and kidney weight (KW) and kidney weight factored
for body weight (KW/BW) are shown in Table 1. Both drugs
causes statistically similar declines in MAP. Despite the greater
degree of glomerular injury in CON rats, mean values for whole
kidney GFR were similar in the three groups. Kidney weights
suggested that both drugs tended to inhibit compensatory
kidney growth in this model.
Micropuncture study
Mean values for body weight (WT), hematocrit (UCT), mean
arterial pressure (MAP), single nephron GFR (SNGFR) and the
flows pressures and resistances governing glomerular ultrafil-
tration measured in rats five weeks after UNX are shown in
Table 2. Body weight was slightly, but significantly lower in the
two treated groups as compared to control rats. AP was
increased in CON rats, and markedly reduced by both NIF and
ENP. As was the case for SBP measured in awake animals, AP
was significantly greater in NIF as compared to ENP rats.
Values for SNGFR were similar in CON and NIF rats. SNGFR
was lower in rats given ENP, although only the difference
between ENP and NIF was statistically significant. Compared
to values observed in normotensive rats or in SHR with two
kidneys [21, GC was elevated in untreated UNX SHR. Both
NIF and ENP tended to reduce P0. An analysis of segmental
resistances suggests that the fall in PGC was largely the result of
the drug induced decline in systemic pressure. Of note, neither
NIF or ENP caused a significant reduction in R. Mean values
for P were reduced to an even greater extent than were those
for GC• This was due to a small but significant increase in T in
the two treated groups. Mean values for QA were similar in the
three groups, however, the average calculated value for Kf was







Table 1. Results of the long term study
Abbreviations are: MAP, mean arterial pressure; C, inulin clear-
ance; KW, kidney weight; BW, body wt; CON, control rats; NIF, rats
fed nifedepine; ENP, rats fed enalapril.
a P < 0.05 vs. CON












Fig. 2. Protein excretion rates in SHR. Groups are as defined in text.
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ec cm5 X 1010mm Hg dyne s
CON 254 47 172 67 12 15 55 5.5 8.1 0.32 74.4 241 0.042 1.97 1.10 3.06
±4 ±1 ±4 ±2 ±0.4 ±1 ±2 ±0.1 ±0.2 ±0.01 ±7.1 ±37 ±0.004 ±0.26 ±0.12 ±0.38
(11) (11) (11) (II) (11) (11) (11) (11) (10) (10) (11) (10) (10) (10) (10) (10)
NIF 23Y 50b 126a.b 60" 14a.b 17a,b 45 5.3 7.6 0.31 882b 289 0.067a 1.ooa 0.73 1.73a
±4 ±1 ±3 ±1 ±0.5 ±1 ±1 ±0.1 ±0.2 ±0.01 ±6.8 ±26 ±0.005 ±0.11 ±0.06 ±0.17
(10) (10) (10) (10) (10) (10) (10) (10) (9) (9) (10) (9) (9) (9) (9) (9)
ENP 23& 45 iioa 59 13 14 46 5.5 7.8 0.28 59.2 226 0.047 0.89a 1.00 1.89a
±5 ±1 ±2 ±2 ±0.3 ±0.5 ±2 ±0.1 ±0.3 ±0.02 ±4.2 ±27 ±0.007 ±0.12 ±0.17 ±0.28
(14) (14) (14) (14) (14) (14) (14) (14) (10) (10) (14) (10) (10) (10) (10) (10)
Data are presented as means ± SE; (N) indicates number of rats in which value was obtained.
a P < 0.05 vs. CON
b P < 0.05 vs. ENP
P = 0.07 vs. CON
difference accounted for the higher filtration rate in NIF as
compared to ENP.
Discussion
Although many factors have been associated with glomerular
sclerosis, a considerable body of evidence suggests that eleva-
tion in glomerular capillary pressure is a key determinant of
injury in SHR. These rats develop marked systemic hyperten-
sion, however, because afferent arteriolar resistance is high,
POC is not elevated in superficial nephrons of intact SHR [2].
Glomerular sclerosis is not observed in these nephrons [1]. If
SHR undergo UNX, afferent resistance declines, P rises and
widespread glomerular sclerosis ensues [21. Furthermore, ma-
neuvers which reduce P in UNX SHR, such as dietary protein
restriction [2] or antihypertensive therapy [10] with either a CE!
or the combination of hydralazine, hydrochiorthiazide and
reserpine, lessen injury in this model.
The present study provides further evidence that elevation in
glomerular pressure damages the kidney. As in our previous
studies, P in untreated UNX SHR was increased compared to
values reported in normotensive rats or in SHR rats with two
kidneys [2]. Administration of either enalapril or nifedipine
prevented this increase in P and reduced the amount of
proteinuria and glomerular sclerosis which developed in these
rats. Thus with respect to pressure, the effects of the calcium
blocker and the angiotensin converting enzyme inhibitor on
glomerular pressure were similar.
Of interest is the observation that K was higher in nifedipine
group than in control rats or those given enalapril. Compared to
normotensive rats, values for Kf are reduced in SHR [2, 19].
This is the case even in weanling rats that are just developing
hypertension [19], suggesting that this is a primary abnormality
of the glomerular microcirculation in this strain. Our findings
indicate that the low Kf is partially reversible and, therefore,
that it may be functional in nature. As reviewed elsewhere,
acute, reversible declines in Kf have been observed in rats in
response to the administration of a variety of vasoactive sub-
stances including angiotensin II [201. It has been suggested that
many of these agents reduce K by binding to specific receptors
on mesangial cells. Receptor occupancy results in the opening
of membrane calcium channels leading to a rise in intracellular
calcium concentration. Mesangial cells then contract causing a
reduction in glomerular capillary filtration surface area and Kf
[20]. Consistent with this hypothesis, calcium channel blockers
have been found to prevent and/or reverse the decline in Kf
which occurs in response to a variety of vasoactive substances
[21]. Thus, it is attractive to speculate that the low Kf in
untreated SHR results from the presence of a vasoactive
substance which contracts mesangial cells and that this effect is
reversed by the calcium antagonist. The identity of substance
responsible for inducing this change cannot be discerned from
our data, however, the finding that Kf was not increased in the
group given enalapril suggests that it was not angiotensin I!.
As noted above, the fact that angiotensin converting enzyme
inhibitors can reduce glomerular pressure has been previously
noted. However, the finding in the present study, that chronic
administration of a calcium channel blocker also prevents
glomerular hypertension is novel. Using video microscopic
techniques, Fleming, Parekh and Steinhausen [22] and
Loutzenhiser, Hayashi and Epstein [23] found that these agents
preferentially dilated the preglomerular vasculature, and there-
fore were predicted to cause GC to remain constant or even
increase. This supposition has largely been confirmed by pre-
vious micropuncture studies in which the effects of calcium
blockers on glomerular hemodynamics have been examined.
Thus, while Anderson et al [241 found that an acute intravenous
infusion of verapamil could lower P0 in rats with remnant
kidneys, Pelayo et al [251 reported that glomerular pressure was
persistently elevated in RK rats that were chronically treated
with this drug. Interpretation of this latter finding is further
complicated by the fact that Pelayo et al [261 administered
verapamil in a dose which lessened glomerular sclerosis but did
not reduce systemic blood pressure. In addition, we have
recently reported that chronic administration of nifedipine
failed to reduce glomerular pressure in rats with either desoxy-
corticosterone-salt (DOC-salt) hypertension [6] or a remnant
kidney [261.
The explanation for the different effects of calcium blockers
on glomerular pressure in the present as compared to previous
studies is uncertain, however, it should be noted that a similar,
model specific pattern of responses has been described for the
combination of hydralazine, hydrochlorthiazide and reserpine
(HHR). In moderate doses, HHR fails to reduce glomerular
pressure or injury in the DOC-salt [11] or RK [9] models. In
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UNX SHR, it prevents glomerular hypertension and signifi-
cantly reduces the prevalence of glomerulosclerosis [10]. The
mechanism by which NIF and HHR reduce GC in the UNX
SHR is suggested by analysis of the changes in afferent and
efferent resistance which occurred in these experiments. In the
RK and DOC-salt models, administration of NIF [6, 261 or
HHR [9, 111 is associated with a selective decline in afferent
resistance that totally offsets the fall in mean arterial pressure.
As was the case in the videomicroscopic studies cited above,
efferent resistance in these micropuncture experiments was
relatively unaffected. However, in UNX SHR given HHR [101
or NIF, not only the afferent, but also the efferent arteriole
dilates, and this leads to a fall in GC Thus, in the present
study, the lower value for RE accounted for the fall in P0 in
nifedipine treated rats even though the difference between
treated and control rats was not statistically significant.
It should be noted that RE failed to decline significantly in the
enalapril treated group. This suggests that the decline in POC in
this group was largely the result of the significant decrease in
mean arterial pressure in this group, and not a specific effect of
enalapril to dilate the efferent arteriole.
Regardless of the mechanism, the tendency for P to decline
in response to therapy in SHR may help to explain why all
antihypertensive agents seem equally effective in reducing
glomerular injury in this model, whereas this is not the case in
RK and DOC-salt rats. An obvious question is: which animal
model more closely mimics the response to therapy of patients
with hypertension and renal disease? The answer to this ques-
tion can only be resolved by randomized, controlled clinical
trials in which the relative efficacy of these different antihyper-
tensive agents in preventing loss of renal function is prospec-
tively analyzed.
It is possible that nifedipine has other beneficial effects on
glomerular structure in addition to its ability to reduce glomer-
ular capillary pressure. Consistent with this hypothesis, we
have reported that nifedipine also lessens glomerular injury in
the RK [26] and DOC-salt [6] models, in the absence of any
significant changes in glomerular hemodynamics. One possibil-
ity suggested by these studies was that nifedipine reduced
sclerosis by inhibiting compensatory kidney growth. Renal
hypertrophy is commonly observed in settings where glomeru-
lar perfusion is increased, and may be an independent risk
factor for glomerular injury [4, 7]. In the present study, kidney
weight was lower in rats treated with either nifedipine or
enalapril. Accordingly, it is possible that the beneficial effect of
these agents on glomerular damage resulted, at least in part,
from inhibition of renal growth.
Another potentially beneficial action of calcium channel
blockers is their ability to inhibit platelet aggregation [27] in
some settings. Of note, antiplatelet agents have been reported
to lessen glomerular injury in rats with remnant kidneys [28].
Although platelet aggregation was not measured in the present
study, it was assessed in a previous experiment in DOC-salt rats
[6]. In that study, platelet aggregation was not altered in rats
given nifedipine, yet glomerular injury was prevented. These
data suggest that the beneficial effect of niledipine does not
result from alterations in platelet function.
Harris and coworkers [29] have reported that oxygen con-
sumption is increased in remnant kidneys and suggested that
this might lead to increased generation of damaging oxygen
radicals. They reported that verapamil lessened oxygen con-
sumption in the isolated perfused remnant kidney and, there-
fore, might ameliorate injury by reducing oxidant stress. While
this is an interesting hypothesis, it should be noted that Nath,
Croatt and Hostetter [30] were unable to detect any evidence of
increased tissue peroxidation or oxidant stress in RK rats fed a
normal protein diet. In addition, we know of no data which
suggests that oxygen consumption is increased in the milder,
UNX SHR model, as it is in the RK model. It is also unknown
whether dihydropyridine calcium channel blockers such as
nifedipine reduce oxygen consumption in a manner similar to
verapamil.
In summary, SHR uninephrectomized at an early age develop
significant proteinuria and glomerular sclerosis by seven
months of age. Glomerular capillary pressure is elevated early
in the course of this disease. Therapy with either enalapril or
nifedipine reduces systemic and glomerular capillary pressure
and lessens glomerular injury in these rats, suggesting that
glomerular hypertension is an important risk factor for progres-
sive glomerular injury. They fail to support the hypothesis that
CEI are superior to calcium channel blockers in their ability to
prevent kidney damage. The relative efficacy of these agents in
retarding progressive kidney failure in man will only be deter-
mined by clinical trials in which the effects of these agents are
examined in a controlled setting.
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